13F

Investor

Tetragon Partners GP Ltd

CIK 0001515070 · filed 2026-05-15 · SEC filing

13F book

$515.1M

Positions

34

10 new · 4 sold

Largest name

54.3%

UiPath, Inc. · PATH

Est. mark

−$97.1M

Price effect on 24 names still held. Flow $131.7M.
NameTickerSharesValueWeightEst. markChange
UiPath, Inc.PATH25.2M$279.8M54.3%−$92.3MAdded−$6.2M
Kolibri Global Energy Inc.KGEI6.83M$37.5M7.3%$10.7MCut$10.3M
Warner Bros. Discovery, Inc.WBD923.7K$25.4M4.9%New
Workiva IncWK250K$14.9M2.9%−$3.99MAdded$1.97M
Lyft, Inc.LYFT1M$13.3M2.6%−$6.07MHeld
Sprinklr, Inc.CXM2.2M$13.2M2.6%−$3.92MHeld
Autolus Therapeutics PlcAUTL9.5M$13.1M2.5%−$5.8MHeld
Celldex Therapeutics Inc New312.3K$9.91M1.9%$1.11MAdded$3.29M
Arrowhead Pharmaceuticals In127.2K$7.98M1.5%−$357.7KAdded$1.54M
Nektar TherapeuticsNKTR103K$7.41M1.4%$2.06MAdded$4.48M
Annexon, Inc.ANNX1.29M$7.16M1.4%$672.1KCut−$3.04M
Pharvaris N.V.PHVS221.6K$6.26M1.2%$97.3KAdded$860K
Alkermes plc.ALKS159.8K$5.65M1.1%$1.04MAdded$1.7M
Agios Pharmaceuticals, Inc.AGIO164.8K$5.58M1.1%$1.07MAdded$1.17M
Immunovant, Inc.IMVT218.5K$5.43M1.1%−$96.4KAdded$1.2M
Praxis Precision Medicines I16K$5.14M1.0%$437.9KCut−$1.63M
Krystal Biotech, Inc.KRYS19.7K$5.08M1.0%$139.2KAdded$2.17M
Dyne Therapeutics, Inc.DYN258.1K$4.68M0.9%−$354.6KAdded−$170.9K
Amylyx Pharmaceuticals, Inc.AMLX317.9K$4.42M0.9%$496.5KAdded$1.12M
MBX Biosciences, Inc.MBX145.5K$4.34M0.8%−$242.2KAdded−$178K
Definium TherapeDFTX200K$3.78M0.7%New
Soleno Therapeutics Inc102.1K$3.42M0.7%New
Axsome Therapeutics, Inc.AXSM20.1K$3.39M0.7%−$273.2KCut−$1.53M
Harmony Biosciences Hldgs In119.3K$3.34M0.6%−$779.4KAdded$243.4K
Silence Therapeutics Plc630.2K$3.32M0.6%−$295.9KAdded$1.1M
Acadia Pharmaceuticals IncACAD144.6K$3.22M0.6%New
Ionis Pharmaceuticals IncIONS41.8K$3.14M0.6%New
MapLight Therapeutics, Inc.MPLT112.1K$2.28M0.4%$310KCut−$610.6K
Relay Therapeutics, Inc.RLAY181.5K$1.81M0.4%New
Snowflake Inc.SNOW10K$1.51M0.3%−$685.4KHeld
Aardvark Therapeutics, Inc.AARD316.6K$1.19M0.2%New
Tectonic Therapeutic, Inc.TECX37.6K$1.16M0.2%New
Ultragenyx Pharmaceutical In39.5K$827K0.2%New
Karyopharm Therapeutics Inc.KPTI53K$295.1K0.1%New

Positions as of Q1 2026. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.